TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22768889

Group type: EXPERIMENTAL
Intervention: Computer application (CA) used by primary care physicians (PCPs)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Control group (no CA used)
Number of subjects: 697
Study: 20702056

Group type: EXPERIMENTAL
Intervention: Peripheral+Evidential (PE)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Peripheral+Evidential+Socio-Cultural (PE+SC)
Number of subjects: 771
Study: 17336417

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil, 8 mg/d (N=24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No treatment (N=23)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (N=24)
Number of subjects: 47
Study: 16341296

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Strength Training (CAST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unsupervised Training (after 3 months of supervised training)
Number of subjects: 20
Study: 12015902

Group type: EXPERIMENTAL
Intervention: Continuous intravenous administration of 12 million international units (MIU) of IL-2 followed by subcutaneous high-dose IL-2 (7.5 MIU, twice daily) for 5 days every 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous IL-2 for 5 days every 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose (3 MIU, twice daily) subcutaneous IL-2 for 5 days every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 0
Study: 9562580

Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (60 microg per square meter of body-surface area subcutaneously once weekly)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 7947528

Group type: EXPERIMENTAL
Intervention: 25 mg oestradiol implants
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 50 mg oestradiol implants
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 75 mg oestradiol implants
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (15 untreated women)
Number of subjects: 45
Study: 3371393

Group type: EXPERIMENTAL
Intervention: Metoprolol CR (controlled-release), 100 mg once daily
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional metoprolol tablets, 100 mg once daily
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Metoprolol CR (controlled-release), 200 mg if needed
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional metoprolol tablets, 200 mg if needed
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: All formulations of metoprolol
Number of subjects: 195
Study: 30520221

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 388

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 388
Study: 29042333

Group type: EXPERIMENTAL
Intervention: IV acetaminophen (1 g every 6 hours up to 18 hours postoperatively)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 140
Study: 27493113

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy for esophageal varices alone (group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Combined treatment: esophagogastric devascularization with splenectomy followed by sclerotherapy (group B)
Number of subjects: 47
Study: 25271603

Group type: EXPERIMENTAL
Intervention: 100 mg of immunologically active gluten daily
Number of subjects: 944

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 944
Study: 22373943

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1217
Study: 19076988

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 28
Study: 18235409

Group type: EXPERIMENTAL
Intervention: First line chemotherapy based on a combination of pemetrexed and cisplatin
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Prophylactic irradiation following drainage or thoracoscopy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Extensive extra‐pleural pneumonectomy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents such as bevacizumab (Avastatin)
Number of subjects: 1000
Study: 15290003

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study: 12518497

Group type: EXPERIMENTAL
Intervention: Surefil with Prime & Bond NT (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prodigy Condensable with Optibond Solo (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Enamel Plus with Prime & Bond NT (Group C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Negative control (20 teeth without Class I preparations)
Number of subjects: 45
Study: 9457906

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal finger blood flow
Number of subjects: 0
Study: 7557058

Group type: EXPERIMENTAL
Intervention: Teldane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Feliberal
Number of subjects: 12
Study: 3292002

Group type: EXPERIMENTAL
Intervention: No-touch isolation technique
Number of subjects: 236

Group type: COMPARATOR
Intervention: Conventional resection technique
Number of subjects: 236
Study: 19497245

Group type: EXPERIMENTAL
Intervention: Quetiapine (300-450 mg/day) plus citalopram (60 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo plus citalopram (60 mg/day)
Number of subjects: 76
Study: 232026

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31783742

Group type: EXPERIMENTAL
Intervention: Management for LTBI entirely within primary care (GPs and community pharmacists)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Referral to secondary care for LTBI management
Number of subjects: 576
Study: 28240622

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oxandrolone + Propranolol
Number of subjects: 92
Study: 25597463

Group type: EXPERIMENTAL
Intervention: Pinna Compensation (PC) feature
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inter-Ear Coordinated Compression (IE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Omnidirectional microphone (Omni)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Omni microphone with PC feature
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Omni microphone with IE
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Omni microphone with both PC and IE features
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unaided localization performance
Number of subjects: 10
Study: 22171722

Group type: EXPERIMENTAL
Intervention: Immediate loading of Straumann implants (SLActive®)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Early loading of Straumann implants (SLActive®)
Number of subjects: 266
Study: 21881030

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 18562409

Group type: EXPERIMENTAL
Intervention: Alcoholic drink
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-alcoholic drink
Number of subjects: 100
Study: 17267740

Group type: EXPERIMENTAL
Intervention: Ferric gluconate 125 mg intravenously with eight consecutive hemodialysis sessions
Number of subjects: 134

Group type: COMPARATOR
Intervention: No iron (control)
Number of subjects: 134
Study: 15577140

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study: 12143473

Group type: EXPERIMENTAL
Intervention: Optiflow dual lumen catheters at 350 ml/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optiflow dual lumen catheters at 500 ml/min
Number of subjects: 20

Group type: COMPARATOR
Intervention: PermCath dual lumen catheters at 300 ml/min
Number of subjects: 20
Study: 9550167

Group type: EXPERIMENTAL
Intervention: Nutrition counseling plus enteral supplementation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Nutrition counseling alone (control group)
Number of subjects: 118
Study: 8034880

Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional coronary angioplasty
Number of subjects: 0
Study: 3294977

Group type: EXPERIMENTAL
Intervention: Azelastine 2 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Azelastine 4 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Azelastine 8 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Azelastine 12 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Azelastine 16 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 31956928

Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplementation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (corn starch)
Number of subjects: 41
Study: 30799375

Group type: EXPERIMENTAL
Intervention: Intracoronary darbepoetin‐α 300 μg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 27279571

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r 800/100 mg once daily)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 273
Study: 25988798

Group type: EXPERIMENTAL
Intervention: Standard-dose pentazocine/naloxone (50/0.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-dose pentazocine/naloxone (25/0.25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23750517

Group type: EXPERIMENTAL
Intervention: PMTO (Parent Management Training Oregon model)
Number of subjects: 238

Group type: COMPARATOR
Intervention: NTC (No Treatment Control)
Number of subjects: 238
Study: 21449785

Group type: EXPERIMENTAL
Intervention: Weight-management (diet)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Weight-management-Plus-Exercise (diet-exercise)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control
Number of subjects: 107
Study: 19922342

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (MLD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 32
Study: 16858211

Group type: EXPERIMENTAL
Intervention: PL-irradiation (100%, 1800 mW)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Light exercise (50% HR reserve)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo-irradiation (10%, 180 mW)
Number of subjects: 24
Study: 12736838

Group type: EXPERIMENTAL
Intervention: Coper subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-coper subjects
Number of subjects: 0
Study: 10052484

Group type: EXPERIMENTAL
Intervention: Prednisolone (125-150 mg i.v.)
Number of subjects: 26
Study: 7866820

Group type: EXPERIMENTAL
Intervention: OCM (omeprazole 20 mg once in the morning, clarithromycin 250 mg and metronidazole 400 mg twice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: OCT (omeprazole 20 mg once in the morning, clarithromycin 250 mg and tetracycline 500 mg twice daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: OCM
Number of subjects: 80

Group type: COMPARATOR
Intervention: OCT
Number of subjects: 80
Study: 1791389

Group type: EXPERIMENTAL
Intervention: Postoperative instillation of 0.02% mitomycin-C
Number of subjects: 147

Group type: COMPARATOR
Intervention: Beta radiation
Number of subjects: 147
Study: 7338582

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 59

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 59
Study: 31858823

Group type: EXPERIMENTAL
Intervention: Standard pelvic floor muscle exercises and oscillating rod therapy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard pelvic floor muscle exercises and relaxation therapy
Number of subjects: 184
Study: 11836674

Group type: COMPARATOR
Intervention: Active Symptom Control (ASC) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASC plus mitomycin vinblastine and cisplatin (MVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASC plus vinorelbine (N; Navelbine)
Number of subjects: 0
Study: 29447133

Group type: EXPERIMENTAL
Intervention: 8-week online course of game‐like cognitive training exercises (3 sessions/week from home)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Active control involving watching documentary videos
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (cognitive training and control)
Number of subjects: 39
Study: 26376944

Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: One-Stage Full-Mouth Disinfection (FMD)
Number of subjects: 90
Study: 24589824

Group type: EXPERIMENTAL
Intervention: Uncertain and negative RTW-expectations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Illness perceptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative RTW-expectations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 0
Study: 22342864

Group type: EXPERIMENTAL
Intervention: Postinjury PUFAs (850 mg/d)
Number of subjects: 65
Study: 20036067

Group type: EXPERIMENTAL
Intervention: Gore-tex bags
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional dressings
Number of subjects: 30
Study: 18618204

Group type: EXPERIMENTAL
Intervention: Alcohol counseling
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control (no alcohol counseling)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Quality of primary care
Number of subjects: 288
Study: 16030123

Group type: EXPERIMENTAL
Intervention: Current/former smokers
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Subjects with >=1 inactive GSTM1 alleles
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Subjects with >=1 inactive GSTT1 alleles among smokers
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Subjects with >=1 inactive GSTT1 alleles among never smokers
Number of subjects: 772
Study: 12022301

Group type: EXPERIMENTAL
Intervention: Trophic feeding (0.5‐1 ml h(‐1)) along with parenteral nutrition
Number of subjects: 80

Group type: COMPARATOR
Intervention: Parenteral nutrition alone
Number of subjects: 80
Study: 10526805

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.07 +/- 0.03 microgram.kg‐1.min‐1) during desflurane-N2O anesthesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (desflurane 2% and nitrous oxide 65%)
Number of subjects: 46
Study: 8770775

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose interleukin-2 (IL-2) at doses of 1, 3, and 6 x 10(6) IU/day, administered once daily 6 days a week for 12 weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose interleukin-2 (IL-2) at doses of 1, 3, and 6 x 10(6) IU/day.
Number of subjects: 20
Study: 1827543

Group type: EXPERIMENTAL
Intervention: GR32191 (120 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6110040

Group type: EXPERIMENTAL
Intervention: Cimetidine therapy (full-dose and maintenance) with food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal diet without cimetidine)
Number of subjects: 0
Study: 30578395

Group type: EXPERIMENTAL
Intervention: FGF21 levels at admission
Number of subjects: 509
Study: 27808529

Group type: EXPERIMENTAL
Intervention: Mindful-eating training
Number of subjects: 348

Group type: COMPARATOR
Intervention: Nutrition DVD
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 348
Study: 27459503

Group type: EXPERIMENTAL
Intervention: HOPE + SSSs
Number of subjects: 60

Group type: COMPARATOR
Intervention: SSSs
Number of subjects: 60
Study: 24571705

Group type: EXPERIMENTAL
Intervention: Early supported discharge scheme
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 14
Study: 22991015

Group type: EXPERIMENTAL
Intervention: Biocompatible PD solutions
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conventional PD solutions (Control)
Number of subjects: 182
Study: 21030879

Group type: EXPERIMENTAL
Intervention: Lisinopril titrated to 80 mg daily and additional antihypertensives to target SBP < 130 mm Hg
Number of subjects: 81
Study: 16943794

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg) on alternate days (ADs) for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chronic tadalafil administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: On-demand (OD) tadalafil administration
Number of subjects: 20
Study: 16258088

Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (continuous infusion of 100 U/kg per day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Normal saline solution (50 mL/day as a continuous infusion)
Number of subjects: 204
Study: 12099321

Group type: EXPERIMENTAL
Intervention: Conventional suturing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Simple V-Y suture
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 23
Study: 10345967

Group type: EXPERIMENTAL
Intervention: Clarithromycin plus omeprazole
Number of subjects: 819

Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 819

Group type: COMPARATOR
Intervention: Ranitidine alone
Number of subjects: 819
Study: 1318081

Group type: EXPERIMENTAL
Intervention: 0.20 mg/kg diazepam
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.12 mg/kg diazepam
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 2934803

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate mixed with lignocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 30
Study: 31741553

Group type: EXPERIMENTAL
Intervention: Intrathecal dexamethasone (8 mg) and levobupivacaine (12.5 mg, 0.5%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levobupivacaine (12.5 mg, 0.5%)
Number of subjects: 60
Study: 29223101

Group type: EXPERIMENTAL
Intervention: Inhalation Anaesthesia (IA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA)
Number of subjects: 0
Study: 27127650

Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 37°C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 41°C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nasal high flow therapy at 37°C and 41°C
Number of subjects: 10
Study: 25803270

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 18
Study: 23868944

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 58
Study: 20544245

Group type: EXPERIMENTAL
Intervention: CYC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CYC + PRED
Number of subjects: 24
Study: 19177949

Group type: EXPERIMENTAL
Intervention: Auditory model
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Blocked‐blocked and blocked‐random practice conditions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Random‐random and blocked‐random practice schedules
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Blocked‐random practice condition
Number of subjects: 80
Study: 16982936

Group type: EXPERIMENTAL
Intervention: Influenza vaccination (inactivated vaccine, administered intramuscularly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Influenza vaccination (live, attenuated vaccine, administered intranasally)
Number of subjects: 0
Study: 14582335

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pirymethamine (SDXP)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined therapy (SDXP/CQ)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Late treatment failure (asymptomatic)
Number of subjects: 160
Study: 11022900

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 106

Group type: COMPARATOR
Intervention: Antihypertensive medication
Number of subjects: 106
Study: 9190662

Group type: EXPERIMENTAL
Intervention: Lidamidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lidamidine with psychotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with psychotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Overall comparison of lidamidine vs placebo
Number of subjects: 40
Study: 7965900

Group type: EXPERIMENTAL
Intervention: Circumferential design
Number of subjects: 134

Group type: COMPARATOR
Intervention: Bar design
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both designs
Number of subjects: 134
Study: 3315593

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31935249

Group type: EXPERIMENTAL
Intervention: Body weight-adjusted dose of palonosetron (1 μg/kg, GI = 40 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fixed dose of palonosetron (75 μg, GII = 40 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Body weight-adjusted dose of palonosetron (1 μg/kg, GI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fixed dose of palonosetron (75 μg, GII)
Number of subjects: 80
Study: 29239763

Group type: EXPERIMENTAL
Intervention: Combat Action Tourniquet (CAT)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Ratcheting Medical Tourniquet (RMT)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Stretch Wrap and Tuck Tourniquet (SWAT‐T)
Number of subjects: 198